Autolus Therapeutics (AUTL) Q4 2018 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2018 earnings summary
9 Nov, 2026Executive summary
Clinical-stage biopharmaceutical business developing programmed T-cell therapies; five programs span six hematological and solid-tumor indications, with no approved products or product-sales revenue.
Four Phase 1/2 proof-of-concept trials in hematological cancers were targeted for completion in 2019; worldwide commercial rights held across the therapy portfolio.
Financial highlights
FY2018 operating loss was £40.4m vs. £18.5m in FY2017; net loss was £31.1m vs. £15.6m.
FY2018 R&D expense was £24.6m vs. £12.9m; administrative expense was £16.8m vs. £7.2m.
Other operating income was £1.0m; finance income £4.1m; income tax credit £5.2m; loss before tax £36.3m.
Cash and cash equivalents were £189.3m at September 30, 2018 vs. £102.3m a year earlier; total assets were £217.7m.
Outlook and guidance
Existing cash was expected to fund current and planned operating expenses and capex into calendar 2021, subject to assumptions; forecasts through 2020 supported the going-concern basis.
Significant losses and expenses were expected to continue as clinical development, regulatory work, manufacturing capacity and commercialization preparations advanced.
Proof-of-concept phases of four Phase 1/2 hematological cancer trials were expected in 2019; AUTO6 NG trial initiation was planned for 2020.
Additional financing may be needed; possible sources include equity, debt, collaborations or strategic transactions, with potential dilution or rights concessions.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026